NDC 66621-0150-02 - ANASCORP
This NDC is not currently matched to an FDA NDC product listing in FDA.report, but it is a valid NDC-form code. FDA.report is showing the available DailyMed label context for the product root.
- Product NDC
- 66621-0150
- Requested NDC
- 66621-0150-02
- Package NDCs from labels
- 66621-0150-1, 66621-0150-2, 66621-0150-02
- Manufacturer
- Rare Disease Therapeutics, Inc | Laboratorios Silanes S.A. de C.V.
- Effective date
- 2025-07-16
- Current FDA listing
- Not matched in FDA.report NDC product tables
DailyMed Labels#
| Label | Manufacturer | Effective date | Type |
|---|---|---|---|
| ANASCORP - Rare Disease Therapeutics, Inc | Laboratorios Silanes S.A. de C.V. | Rare Disease Therapeutics, Inc | Laboratorios Silanes S.A. de C.V. | 2025-07-16 | PLASMA DERIVATIVE |
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 66621-0150-1 | ANASCORP | 10 mL in 1 VIAL | INJECTION, POWDER, LYOPHILIZED, | 10 | 20 | |
| 66621-0150-2 | ANASCORP | 1 in 1 CARTON | INJECTION, POWDER, LYOPHILIZED, | 1 | 20 |
DailyMed Dashboard NDC Coverage#
| NDC | Dashboard title | SPL version | Validation | Dashboard ZIP |
|---|---|---|---|---|
| 66621-0150 | ANASCORP (CENTRUROIDES (SCORPION) IMMUNE F(AB)2 (EQUINE)) INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION [RARE DISEASE THERAPEUTICS, INC] | 19 | Current NDC, Legacy NDC, 2 package rows | 20240517_5cb65048-a30c-48e5-8bc8-897983d08068.zip |
DailyMed Billing Units#
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 66621-0150-1 | EA - Each | 66621-0150 | c1b5574c-e204-4436-8ecb-4d6e932832ec | 1 | 2012-07-24 |
| 66621-0150-2 | EA - Each | 66621-0150 | 7fff0a50-b77a-4f63-a823-597245b414fd | 1 | 2017-08-11 |
DailyMed Socrata Ingredients#
| Ingredient | Type | UNII | DailyMed label | SPL version | Uploaded |
|---|---|---|---|---|---|
| CENTRUROIDES FAB2 ANTIVENIN (EQUINE) | ACTIVE INGREDIENT | DDA050FCEA | ANASCORP (CENTRUROIDES (SCORPION) IMMUNE F(AB)2 (EQUINE)) INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION [RARE DISEASE THERAPEUTICS, INC] | 3 | |
| CENTRUROIDES FAB2 ANTIVENIN (EQUINE) | ACTIVE MOIETY | DDA050FCEA | ANASCORP (CENTRUROIDES (SCORPION) IMMUNE F(AB)2 (EQUINE)) INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION [RARE DISEASE THERAPEUTICS, INC] | 3 |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| ANASCORP | CENTRUROIDES (SCORPION) IMMUNE F(AB)2 (EQUINE) | Rare Disease Therapeutics, Inc | 5cb65048-a30c-48e5-8bc8-897983d08068 | 2025-07-16 | Warnings, Adverse reactions | BLA125335 66621-0150-2 66621-0150-1 66621-0150 66621015002 1119989 1119993 d0c33dec-842e-4cc0-9d8f-515d6efd8a0c 5cb65048-a30c-48e5-8bc8-897983d08068 DDA050FCEA |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.